WO2002057316A1 - Nouvel anticorps monoclonal - Google Patents
Nouvel anticorps monoclonal Download PDFInfo
- Publication number
- WO2002057316A1 WO2002057316A1 PCT/JP2001/011493 JP0111493W WO02057316A1 WO 2002057316 A1 WO2002057316 A1 WO 2002057316A1 JP 0111493 W JP0111493 W JP 0111493W WO 02057316 A1 WO02057316 A1 WO 02057316A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- monoclonal antibody
- antibody
- human
- bst2
- cells
- Prior art date
Links
- 210000004027 cell Anatomy 0.000 claims abstract description 132
- 101000740785 Homo sapiens Bone marrow stromal antigen 2 Proteins 0.000 claims abstract description 92
- 102000047829 human BST2 Human genes 0.000 claims abstract description 53
- 239000012634 fragment Substances 0.000 claims abstract description 52
- 108091007433 antigens Proteins 0.000 claims abstract description 28
- 102000036639 antigens Human genes 0.000 claims abstract description 28
- 239000000427 antigen Substances 0.000 claims abstract description 27
- 230000027455 binding Effects 0.000 claims abstract description 24
- 239000004480 active ingredient Substances 0.000 claims abstract description 3
- 102100037086 Bone marrow stromal antigen 2 Human genes 0.000 claims description 41
- 210000004408 hybridoma Anatomy 0.000 claims description 40
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 37
- 239000003814 drug Substances 0.000 claims description 24
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 24
- 239000000126 substance Substances 0.000 claims description 22
- 150000001413 amino acids Chemical class 0.000 claims description 20
- 206010028980 Neoplasm Diseases 0.000 claims description 19
- 108090000623 proteins and genes Proteins 0.000 claims description 17
- 229940124597 therapeutic agent Drugs 0.000 claims description 16
- 208000034578 Multiple myelomas Diseases 0.000 claims description 13
- 229930126263 Maytansine Natural products 0.000 claims description 12
- 238000001816 cooling Methods 0.000 claims description 12
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 238000012258 culturing Methods 0.000 claims description 8
- 229940127089 cytotoxic agent Drugs 0.000 claims description 8
- 239000002246 antineoplastic agent Substances 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 231100000699 Bacterial toxin Toxicity 0.000 claims description 5
- 239000000688 bacterial toxin Substances 0.000 claims description 5
- 208000019420 lymphoid neoplasm Diseases 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 239000000651 prodrug Substances 0.000 claims description 4
- 229940002612 prodrug Drugs 0.000 claims description 4
- 210000004989 spleen cell Anatomy 0.000 claims description 4
- 238000010367 cloning Methods 0.000 claims description 3
- 230000008685 targeting Effects 0.000 claims description 3
- 210000005260 human cell Anatomy 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 239000000203 mixture Substances 0.000 abstract description 9
- 229940126585 therapeutic drug Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 description 28
- 238000006243 chemical reaction Methods 0.000 description 18
- 239000002953 phosphate buffered saline Substances 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 239000012228 culture supernatant Substances 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 13
- 239000000872 buffer Substances 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 12
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 239000012894 fetal calf serum Substances 0.000 description 10
- 230000001939 inductive effect Effects 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 230000000259 anti-tumor effect Effects 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- -1 -1 (Treon et al. Substances 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 8
- 229940024606 amino acid Drugs 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000003053 immunization Effects 0.000 description 8
- 238000003752 polymerase chain reaction Methods 0.000 description 8
- 239000013598 vector Substances 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- 108060003951 Immunoglobulin Proteins 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 7
- 238000002649 immunization Methods 0.000 description 7
- 102000018358 immunoglobulin Human genes 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 239000012099 Alexa Fluor family Substances 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 230000000903 blocking effect Effects 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 230000009257 reactivity Effects 0.000 description 6
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 210000001185 bone marrow Anatomy 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 210000004976 peripheral blood cell Anatomy 0.000 description 5
- 239000008363 phosphate buffer Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 241000701447 unidentified baculovirus Species 0.000 description 5
- QWPXBEHQFHACTK-KZVYIGENSA-N (10e,12e)-86-chloro-12,14,4-trihydroxy-85,14-dimethoxy-33,2,7,10-tetramethyl-15,16-dihydro-14h-7-aza-1(6,4)-oxazina-3(2,3)-oxirana-8(1,3)-benzenacyclotetradecaphane-10,12-dien-6-one Chemical compound CN1C(=O)CC(O)C2(C)OC2C(C)C(OC(=O)N2)CC2(O)C(OC)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 QWPXBEHQFHACTK-KZVYIGENSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 4
- 241000283707 Capra Species 0.000 description 4
- 241000282693 Cercopithecidae Species 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 102000004889 Interleukin-6 Human genes 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- QWPXBEHQFHACTK-UHFFFAOYSA-N Maytansinol Natural products CN1C(=O)CC(O)C2(C)OC2C(C)C(OC(=O)N2)CC2(O)C(OC)C=CC=C(C)CC2=CC(OC)=C(Cl)C1=C2 QWPXBEHQFHACTK-UHFFFAOYSA-N 0.000 description 4
- 239000012979 RPMI medium Substances 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 238000009175 antibody therapy Methods 0.000 description 4
- 210000000628 antibody-producing cell Anatomy 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 210000004180 plasmocyte Anatomy 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 3
- 238000011579 SCID mouse model Methods 0.000 description 3
- 241000831652 Salinivibrio sharmensis Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 108700019146 Transgenes Proteins 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229940088623 biologically active substance Drugs 0.000 description 3
- 230000007910 cell fusion Effects 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 102000013415 peroxidase activity proteins Human genes 0.000 description 3
- 108040007629 peroxidase activity proteins Proteins 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000009261 transgenic effect Effects 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 239000011592 zinc chloride Substances 0.000 description 3
- 235000005074 zinc chloride Nutrition 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 241000272875 Ardeidae Species 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 108010051118 Bone Marrow Stromal Antigen 2 Proteins 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 241000725101 Clea Species 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 2
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 2
- 241000282560 Macaca mulatta Species 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 108010039491 Ricin Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 108020005038 Terminator Codon Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 125000005414 dithiopyridyl group Chemical group 0.000 description 2
- 239000012149 elution buffer Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 238000001215 fluorescent labelling Methods 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 229940027941 immunoglobulin g Drugs 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 208000031223 plasma cell leukemia Diseases 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229910052713 technetium Inorganic materials 0.000 description 2
- GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- OPKAUPROPWPLTQ-LURJTMIESA-N (2s)-2-[methyl-[3-(methyldisulfanyl)propanoyl]amino]propanoic acid Chemical compound CSSCCC(=O)N(C)[C@@H](C)C(O)=O OPKAUPROPWPLTQ-LURJTMIESA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- HIEMXKNAEWDJLF-UHFFFAOYSA-N 3-[[1-(2,5-dioxopyrrolidin-1-yl)-2h-pyridin-2-yl]sulfanyl]propanoic acid Chemical compound OC(=O)CCSC1C=CC=CN1N1C(=O)CCC1=O HIEMXKNAEWDJLF-UHFFFAOYSA-N 0.000 description 1
- PMYDPQQPEAYXKD-UHFFFAOYSA-N 3-hydroxy-n-naphthalen-2-ylnaphthalene-2-carboxamide Chemical compound C1=CC=CC2=CC(NC(=O)C3=CC4=CC=CC=C4C=C3O)=CC=C21 PMYDPQQPEAYXKD-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- YPXQSGWOGQPLQO-UHFFFAOYSA-N 5-nitro-1,3-dihydrobenzimidazole-2-thione Chemical compound [O-][N+](=O)C1=CC=C2N=C(S)NC2=C1 YPXQSGWOGQPLQO-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 102100034612 Annexin A4 Human genes 0.000 description 1
- 108090000669 Annexin A4 Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 244000041633 Grewia tenax Species 0.000 description 1
- 235000005612 Grewia tenax Nutrition 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 1
- 101001024703 Homo sapiens Nck-associated protein 5 Proteins 0.000 description 1
- 101000766306 Homo sapiens Serotransferrin Proteins 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 208000013038 Hypocalcemia Diseases 0.000 description 1
- 206010058002 Hypoglobulinaemia Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
- 108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 102000010781 Interleukin-6 Receptors Human genes 0.000 description 1
- 108010038501 Interleukin-6 Receptors Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 101100384355 Mus musculus Ctnnbip1 gene Proteins 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 102100036946 Nck-associated protein 5 Human genes 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- PVNFMCBFDPTNQI-UIBOPQHZSA-N [(1S,2R,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] acetate [(1S,2R,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] 3-methylbutanoate [(1S,2R,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] 2-methylpropanoate [(1S,2R,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] propanoate Chemical compound CO[C@@H]1\C=C\C=C(C)\Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(C)=O)[C@]2(C)OC2[C@H](C)[C@@H]2C[C@@]1(O)NC(=O)O2.CCC(=O)O[C@H]1CC(=O)N(C)c2cc(C\C(C)=C\C=C\[C@@H](OC)[C@@]3(O)C[C@H](OC(=O)N3)[C@@H](C)C3O[C@@]13C)cc(OC)c2Cl.CO[C@@H]1\C=C\C=C(C)\Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(=O)C(C)C)[C@]2(C)OC2[C@H](C)[C@@H]2C[C@@]1(O)NC(=O)O2.CO[C@@H]1\C=C\C=C(C)\Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(=O)CC(C)C)[C@]2(C)OC2[C@H](C)[C@@H]2C[C@@]1(O)NC(=O)O2 PVNFMCBFDPTNQI-UIBOPQHZSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000011230 antibody-based therapy Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 1
- 229930195731 calicheamicin Natural products 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000032459 dedifferentiation Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000007973 glycine-HCl buffer Substances 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 description 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical group I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 230000000705 hypocalcaemia Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- XMBWDFGMSWQBCA-YPZZEJLDSA-N iodane Chemical compound [125IH] XMBWDFGMSWQBCA-YPZZEJLDSA-N 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 125000003010 ionic group Chemical group 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000001325 log-rank test Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940093430 polyethylene glycol 1500 Drugs 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000019585 progressive encephalomyelitis with rigidity and myoclonus Diseases 0.000 description 1
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- WHMDPDGBKYUEMW-UHFFFAOYSA-N pyridine-2-thiol Chemical compound SC1=CC=CC=N1 WHMDPDGBKYUEMW-UHFFFAOYSA-N 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000011655 sodium selenate Substances 0.000 description 1
- 235000018716 sodium selenate Nutrition 0.000 description 1
- 229960001881 sodium selenate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 150000003573 thiols Chemical group 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Definitions
- the present invention relates to an antibody that recognizes a human BST2 antigen present on a cell surface. Specifically, the present invention relates to a monoclonal antibody or a functional fragment thereof that binds to the human BST2 antigen and can be localized inside the cell by internalization to the cell. The present invention also relates to a conjugate obtained by binding the monoclonal antibody or a functional fragment thereof to a therapeutic reagent.
- Cancer is the leading cause of death in Japan, and the number of patients is increasing year by year. There is a strong demand for the development of highly effective and safe drugs and treatments.
- One type of hematopoietic tumor, multiple myeloma, is an incurable B-cell tumor that causes abnormalities in the final stages of B-cell differentiation.
- the course of multiple myeloma is similar to that of end-stage plasma cell leukemia (Plasma cell leukemia), and the secretion of immunoglobulin chains in neoplasms characterized by the accumulation of clones of plasma cells Often accompanied by Tumor bone marrow infiltration involves uncontrolled proliferation of myeloma cells with numerous complications such as anemia, hypoglobulinemia, and bacterial infection. Also, in multiple myeloma, increased levels of interleukin 6 (IL6) result in increased osteoclasts that lead to bone pain, fractures and hypocalcemia. High concentrations of myeloma immunoglobulin and hypercalcemia are often associated with renal failure.
- IL6 interleukin 6
- Chemotherapy is the standard treatment with multidrug therapy using melphalan and prednisolone, but the disease recurs after induction of remission with an intermediate duration of about 2 years (Alexanian et al., New Zealand). Engl and J Medicine., 1994 Vol 330: 484).
- these drugs not only act specifically on tumor cells, but also show toxicity on normal cells, causing serious side effects and a limited therapeutic effect.
- Ultra-high-dose chemotherapy combined with hematopoietic stem cell transplantation since the 1980s It is being actively studied but its clinical efficacy remains low.
- IL-6 is thought to be a major growth factor for multiple myeloma cells (Kawano et al., Nature., 1988 Vol 332: 83; Klein et al., Blood., 1991 Vol 73: 517).
- Treatment of multiple myeloma patients with neutralizing antibodies against IL-6 or IL-6 receptor has been attempted to block the -6 signaling system.
- suppression of myeloma cell growth was observed in patients with leukemia mutations in the disease, the tumor recurred and was not clinically effective (Bataille et al., Blood., 1995 Vol.
- CD19 (Grossbard et al., Br J Haematol., 1998 Voll02: 509)
- CD20 Humanssein et al., Blood., 1999 Yol94 [Suppl.1]: 313)
- CD38 Methy et al., Semin Hematol., 1999 Vol36 [Suppl.3]: 30
- CD54 Human et al., Cancer Res., 1995 Vol55: 610
- CD138 (Wijdenes et al., Br J Haematol., 1996 Vol94: 318)
- Muc Myeloma cell-expressing antigens such as -1 (Treon et al., Blood., 1999 Vol93: 1287) have been reported as candidates for target antigens for antibody therapy, but have not yet
- bone marrow stromal antigen 2 (also referred to as BST2 or HM1.24 antigen) has been reported as one of the antigens highly expressed in myeloma cells (Goto et al., Blood., 1994). Vol 84: 1922; O tomo et al., Biochem Biopliys Res Com., 1999 Vol 258: 583).
- BST2 is a type II transmembrane glycoprotein consisting of 180 amino acid residues and having a molecular weight of about 30 kDa. Cells that form homodimers by SS binding Expressed on the membrane.
- BST2 protein is not expressed in normal peripheral blood cells, bone marrow cells, reactive lymphocytes, liver, kidney, heart, etc., but is highly expressed in plasma cells and myeloma cells. Although the detailed biological activity is not yet known, BST2 is thought to be involved in terminal differentiation of B cells (Ishikawa et al., Genomics., 1995 Vol 26: 527). As for antibodies against human BST2, a mouse monoclonal antibody (Goto et al., Blood., 1994 Vol 84: 1922) produced by immunizing a non-human mammal such as a mouse with a human BST2-expressing cell line has been reported. ing.
- BST2 has been reported to be expressed not only in myeloma but also in other lymphoid tumors
- anti-BST2 antibody therapy is expected to exert an effect on these tumors.
- these antibodies do not have the activity to induce BST2 modulat ion by antibody conjugation (Ozaki et al., Hematology, Oncology, 2000 Vol. 41: 128), and increase the efficacy and side effects of therapeutic agents such as chemotherapeutic agents and radionuclides.
- No anti-BST2 antibody has been reported yet that induces rapid internalization, which can be greatly reduced.
- an antibody that binds to an antigen protein expressed on the cell surface and induces internalization inside the cell can be generally obtained, but such an antibody is used for all cell surface antigens. It is not always clear if the information is obtained.
- An object of the present invention is to develop an antibody capable of binding to human BST2 and having an activity of inducing localization (internalization) in a cell such as a tumor cell that expresses human BST2, thereby simultaneously treating the disease.
- An object of the present invention is to provide a therapeutic agent based on a novel mechanism of action for the treatment of difficult diseases such as multiple myeloma.
- the present inventors have conducted intensive studies on the production of antibodies against human BST2, and have obtained an anti-BST2 antibody with rapid internalization properties into target cells. Succeeded and completed the present invention.
- the present invention includes the following inventions.
- a monoclonal antibody or a functional fragment thereof which binds to a human BST2 antigen present on a cell surface and can be localized inside the cell by internalization on the cell.
- the cells are RPMI8226 strain (ATCC CCL-155), and after binding the monoclonal antibody under ice-cooling, the internalization proceeds within 120 minutes after the start of culture at 37,
- the average fluorescent intensity of the fluorescent substance indicating the abundance of the human BST2 / monoclonal antibody complex on the cell surface is 50% or less of the time when the culture was started.
- the monoclonal antibody of (1) or a functional fragment thereof is the monoclonal antibody of (1) or a functional fragment thereof.
- the cells are RPMI8226 strain, and after binding the monoclonal antibody under ice-cooling, internalization proceeds within 90 minutes after the start of culture at 37 ° C, and the (1) The monoclonal antibody or a functional fragment thereof according to (1), wherein the average fluorescent intensity of the fluorescent substance indicating the abundance of the human BST2 / monoclonal antibody complex is 50% or less at the start of the culture.
- the cells are RPMI8226 strain, and after binding the monoclonal antibody under ice-cooling, internalization proceeds within 60 minutes after the start of culture at 37 ° C.
- the cell is RPMI8226 strain, and after the monoclonal antibody is bound under ice-cooling, internalization proceeds within 30 minutes after the start of culture at 37, and human cells on the cell surface (1)
- the cells are RPMI8226 strain, and after binding the monoclonal antibody under ice-cooling, internalization proceeds within 15 minutes after the start of culture at 37, and the cells on the cell surface
- the monoclonal antibody of (1) or a functional fragment thereof is the monoclonal antibody of (1) or a functional fragment thereof.
- a pharmaceutical composition targeting human BST2-expressing cells comprising the complex of (12) or (13) as an active ingredient.
- a hybridoma was prepared by fusing spleen cells of a non-human animal immunized with a polypeptide containing at least a partial amino acid sequence of the human BST2 antigen with myeoma cells, and a human BST2 antigen was prepared from the hybridoma. Selecting a hybridoma that produces an antibody that binds to the human BST2 antigen produced from the selected hybridoma, and reacting the antibody with a cell that expresses a human BS antigen, and culturing the cell. 2. The method for producing a monoclonal antibody or a functional fragment thereof according to claim 1, wherein selection is performed using a decrease in the abundance of the human BST2 / antibody complex on the cell surface as an index.
- the present invention relates to the monoclonal antibody or the antibody according to any one of the above (1) to (11).
- Biologically active substance refers to any biological change in a cell into which the substance has been introduced, such as (1) promotion or suppression of proliferation of the cell, (2) promotion or suppression or dedifferentiation of differentiation, (3) A substance that can cause changes in the action such as signal transmission from the cell to another cell, and (4) Cell death.
- chemotherapeutic agents for chemotherapeutic agents, radionuclides, bacterial toxins, various cytokins or hormones, transcription factors, enzymes involved in sugar chain synthesis or degradation, or cells.
- examples include DNA or RNA.
- the definitions of the terms used in the present specification are as follows.
- Human BST2 is an abbreviation of bone marrow strom ant igen 2, a type II transmembrane glycoprotein consisting of 180 amino acid residues and having a molecular weight of about 30 kDa, which forms a homodimer through disulfide bonds to form plasma cells and bone marrow.
- proteins that are specifically expressed on the cell membrane of cells such as tumor cells (eg, Goto et al., Supra; Ohtomo et al., Supra).
- Internalization or “rapid internalization” refers to the non-specific uptake of cells by a mechanism called phagocytosis (endocytosis). Rather, the antibody forms an immune complex with the cell surface antigen and is taken up in the cell in a short time. For example, depending on the reaction conditions and the properties of the antibody and antigen, etc., in general, when an antibody is taken up by this mechanism, the immune complex of the antibody and the receptor moves on the cell surface in an energy-dependent manner after binding, Eventually, after concentration (caving), it is taken up into cells within one to several minutes, at the latest within 12 hours.
- An antibody that binds to an antigen on the surface of a cell and is taken into a cell by internalization may be referred to herein as an “antibody having an inducing activity”.
- the average fluorescence intensity of the fluorescent substance indicating the abundance of the human BST2 / monoclonal antibody complex on the cell surface is 50% or less of that at the start of the culture '' means that cells having the human BST2 antigen on the cell surface
- the amount of human BST2 / monoclonal antibody complex formed by immunological reaction with human BST2 on the cell surface at the start of culturing is determined after a certain period of time relative to the abundance of human BST2 / monoclonal antibody complex 100.
- the ratio of the remaining amount of the complex is It means that it is 50% or less, in other words, that 50% or more of the anti-BST2 antibody forming the immunological complex has been taken up into the cell by the internalization.
- Prodrug refers to a precursor drug that is converted into an active drug by the action of endogenous enzymes and the like when administered in vivo.
- “Chemotherapeutic agent” refers to a drug that selectively treats a disease caused by a tumor or the like by acting on the pathogen without causing significant damage to the patient.
- one letter of the alphabet used to represent an amino acid means the following amino acid.
- G glycine, (A) alanine, (V) valine, (L) leucine, (I) isoleucine, (S) serine, (T) threonine, (D) aspartic acid, (E) glutamic acid, (N ) Asparagine, (Q) glutamine, (10 lysine, (R) arginine, (0 cysteine, (M) methionine, (F) fenylalanine, (Y) tyrosine, (W) tributofan, (H) histidine, (P
- the letters of the alphabet used to represent DNA are as follows: (A) adenine, (C) cytosine, (G) guanine, (T) thymine. The invention will be described in detail.
- Human BST2 is known in the technical field such as a chemical synthesis method, a cell culture method, and the like, in addition to a genetic recombination technique, based on a known base sequence or amino acid sequence (SEQ ID NO: 1 or 2, respectively). It can be produced by appropriately using a method.
- the partial sequence of human BST2 can be produced by a genetic recombination technique or a chemical synthesis method according to a method known in the technical field described later, or human BST2 can be appropriately cleaved using a protease. By doing so, it can be manufactured.
- the antibodies of the present invention include various anti-human BST2 monoclonal antibodies characterized by having internalization-inducing properties.
- Examples of the antibody include an anti-human BST2 monoclonal antibody as described in Examples 7 to 15 below, or the amino acid sequence of each of the heavy chain and / or light chain constituting the antibody.
- monoclonal antibodies consisting of heavy and / or light chains which have internalization-inducing properties.
- the partial modification (deletion, substitution, insertion, addition) of the amino acid as described above into the amino acid sequence of the antibody of the present invention is introduced by partially modifying the nucleotide sequence encoding the amino acid sequence. can do.
- the antibodies of the present invention include antibodies having any of the immunoglobulin classes and subclasses, and are preferably antibodies having the human immunoglobulin class and subclass.
- preferred classes and subclasses are immunoglobulin G (IgG). , Especially IgGl and IgG4, with the preferred light chain being /.
- a preferred example of the antibody or a fragment thereof of the present invention is that the antibody or the fragment thereof is bound to a myeloma cell line RPMI8226 (ATCC CCL-155) under ice-cooling, and then cultured at 37 ° C. for about 120 minutes. Within, preferably within about 90 minutes, more preferably within about 60 minutes, particularly preferably within about 30 minutes, even more preferably within about 15 minutes, and the human BST2 / antibody on the cell surface The average fluorescence intensity of the fluorescent substance indicating the abundance of the BST2 antibody complex is 50% or less at the start of the culture.
- Another preferred example of the antibody or a fragment thereof of the present invention recognizes an epitope composed of at least eight consecutive or discontinuous amino acid residues in the amino acid sequence of human BST2 (SEQ ID NO: 2). And a sequence comprising a monoclonal antibody or a fragment thereof having internalization-inducing properties.
- Still another preferred example of the antibody of the present invention or a fragment thereof is an antibody having a property of cross-reacting with human BST2 and monkey BST2.
- Such antibodies are expected to recognize the same or very similar epitope structures in human BST2 and monkey BST2, and various tests using monkeys as experimental animals are possible prior to human clinical trials. It has the advantage of being capable.
- a specific example of such an antibody is an antibody produced by hybridoma 9-16-1 (FERM BP-7821) or hybridoma b-76-8 (FE West BP-7822).
- the antibody fragment in the present invention means a part of the antibody as defined above, and specifically, F (ab ') 2, Fab', Fab, Fv, disuplpide-1 inked FV, Single- Chain FV (scFV) and polymers thereof (DJ King., Applicat ions and Engineering of Monoclonal Ant ibodies., 1998 TJ International Ltd.).
- Such an antibody fragment can be obtained by a conventional method, for example, digestion of an antibody molecule with a protease such as papain or pepsin, or a known genetic engineering technique.
- “Functional fragment” refers to a fragment of an antibody that specifically binds to an antigen to which the antibody specifically binds.
- the antibody of the present invention can be produced, for example, by the following method. That is, for example, human BST2 or a part thereof as defined above, or a conjugate with an appropriate substance (for example, bovine serum albumin, etc.) for enhancing the antigenicity of the antigen, or human BST2 on the cell surface If necessary, immunostimulants
- Monoclonal antibodies are prepared by preparing hybridomas from antibody-producing cells obtained from immunized animals and myeloma cells (myeloma cells) that are not capable of producing autoantibodies, cloning the hybridomas, and reacting with the antigen used for immunization. To produce a monoclonal antibody exhibiting a specific affinity, and selecting a clone having internalization-inducing properties by the method described below.
- the antibody of the present invention is a human antibody by using a non-human animal that retains a human antibody gene that has not been rearranged and produces a human antibody specific to the immunogen by immunization.
- the human antibody means an antibody that is an expression product of a human-derived antibody gene, or a functional fragment thereof.
- Cell fusion is performed, for example, by mixing antibody-producing cells and myeloma cells in a highly concentrated polymer solution such as polyethylene glycol (e.g., a molecular weight of 1500 to 6000), usually for about 30 to 40, for about 1 to 10 minutes.
- a highly concentrated polymer solution such as polyethylene glycol (e.g., a molecular weight of 1500 to 6000), usually for about 30 to 40, for about 1 to 10 minutes.
- Screening of hybridoma clones producing monoclonal antibodies can be performed by culturing hybridomas, for example, in a microtiter plate, and determining the reactivity of the culture supernatant in the growing wells for immunogens by ELISA, for example. And the like, and immunological methods such as radioimmunoassay and fluorescent antibody method.
- the hybridoma For production of a monoclonal antibody from a hybridoma, the hybridoma can be cultured in vitro and isolated from the culture supernatant. It can also be isolated from ascites by culturing it in vivo in ascites of mice, ruds, guinea pigs, hamsters, or egrets.
- a gene encoding a monoclonal antibody is cloned from an antibody-producing cell such as a hybridoma and inserted into an appropriate vector, which is then used as a host (for example, mammalian cell strains such as Chinese hamster ovary (CH0) cells, Escherichia coli, Yeast cells, insect cells, plant cells, etc.) to produce recombinant antibodies using genetic recombination technology (PJ Delves., ANTIBODY PRODUCTION ESSENTIAL TECHNIQUES., 1997 WILEY, P Shepherd and C.
- a host for example, mammalian cell strains such as Chinese hamster ovary (CH0) cells, Escherichia coli, Yeast cells, insect cells, plant cells, etc.
- transgenic animals goats, sheep or pigs, in which the gene of the antibody of interest is incorporated into the endogenous gene, are prepared using transgenic animal production technology, and the antibody is extracted from the milk of the transgenic animal. It is also possible to obtain large amounts of monoclonal antibodies derived from genes.
- hybridomas When hybridomas are cultured in vitro, the hybridomas are grown, maintained, and stored in accordance with various conditions such as the characteristics of the cell type to be cultured, the purpose of the test and research, and the culture method.
- a known nutrient medium or a known basal medium as used to produce monoclonal antibodies It can be carried out using any nutrient medium derived and prepared therefrom.
- the produced monoclonal antibody may be obtained by a method known in the art, for example, chromatography using a protein A column, ion exchange chromatography, water-phobic chromatography, ammonium sulfate precipitation, gel filtration, affinity mouth chromatography, etc. Purification can be performed by combining them.
- the monoclonal antibody or a fragment thereof of the present invention produced by the above method can be conjugated with a therapeutic agent to form a complex that can be used for therapeutic purposes such as missile therapy.
- a therapeutic agent which bind to the antibody, but are not limited to, Yodo (131 Iodine: 131 I, Iodine 125 1), Lee Tsu Application Benefits um (90 Yt trium: 90 Y) , b down-di Um ⁇ ! ! : Radionuclide (LW.
- Bacterial toxins such as (Pseudomonas exotoxin), diphtheria toxin, and ricin (Ricin), and chemotherapeutic agents such as methotrexate, mitomycin, and calixamicin (Calicheamicin)
- Maytans inoid which can be converted into a prodrug by binding to an antibody, is preferred (Chari et al., Cancer Res., 1992 Vol. 52: 127, Liu et al., Proc Natl Acad Sc USA, 1996 Vol. 93). : 8681).
- the linkage between the antibody and the therapeutic agent may be either covalent or non-covalent (eg, ionic).
- therapeutic agents that have a functional group (for bacterial toxins or chemotherapeutic agents) that can form a bond with an ionic group (for radionuclide) that can form a complex with the coordinating group.
- the complex of the present invention can be obtained by bringing the antibody into contact with an antibody. Alternatively, a biotin-avidin system could be used in forming the complex.
- the therapeutic agent is a protein or peptide, it can be produced as a fusion protein of the antibody and the protein or peptide by genetic engineering. It is.
- Nshinoido (Maytans inoid) compound bound antibody can be made (Chari et aL, Cancer Res, 1992 Vol52:. 127, US Patent 5, 208, 020) 0 maytansine or Ansami toc in P-3 is reduced with lithium hydride aluminum to prepare maytansinol.
- the prepared maytansinol is esterified with N-methyl-N- (methyldithiopropanoyl) -L-alanine in the presence of dicyclohexylcarbodiimide and zinc chloride, and then purified by a silica gel column etc. Then, a maytansine derivative ( May-SS_Me) is prepared.
- the antibody is reacted with N-succinimidyl-3- (2-pyridylthio) propionic acid or the like or succinimidyl-4- (N-maleimidomethyl) cyclohexane-1-carboxylic acid or the like, and the antibody is reacted with a dithiopyridyl group or a maleimide group, respectively.
- May-SH prepared by reducing May-SS-Me with dithiothreitol or the like, is reacted with an antibody having a dithiopyridyl group or a maleimide group introduced therein to produce a maytansinoid compound-bound antibody.
- compositions containing the anti-human BST2 antibody of the present invention or the anti-human BST2 antibody conjugated to the above-mentioned therapeutic agent is also included in the scope of the present invention.
- the composition should contain a therapeutically effective amount of the therapeutic agent and will be formulated into various forms for oral and parenteral administration.
- a therapeutically effective amount refers to an amount that gives a therapeutic effect for a given symptom or administration schedule.
- the composition of the present invention may contain, in addition to the antibody, physiologically acceptable additives in pharmaceutical preparations, such as diluents, preservatives, solubilizers, emulsifiers, adjuvants, antioxidants, isotonic agents, and excipients.
- agent and carrier may be included. It can also be a mixture with other drugs such as other antibodies or antibiotics.
- Suitable carriers include, but are not limited to, saline, phosphate buffered saline, phosphate buffered saline glucose, and buffered saline. Further, it may contain stabilizers such as amino acids, saccharides, and surfactants, which are well known in the art, and an agent for preventing adsorption to the surface.
- stabilizers such as amino acids, saccharides, and surfactants, which are well known in the art, and an agent for preventing adsorption to the surface.
- examples of the form of the preparation include a lyophilized preparation (in this case, it can be reconstituted by adding a buffered aqueous solution as described above), a sustained release preparation, an enteric preparation, an injection or an infusion.
- the route of administration may be oral, or parenteral, including intravenous, intramuscular, subcutaneous and intraperitoneal injection or drug delivery, but the optimal route will be selected by studies using animals.
- a method in which the composition of the present invention is brought into direct contact with the affected part of a patient may be possible.
- the dose will be determined as appropriate by conducting tests in animals and conducting clinical studies. In general, the patient's condition or severity, age, weight, sex, etc., should be considered.
- the antibody or pharmaceutical composition of the present invention can be applied to the treatment or prevention of various diseases or conditions that may be caused by cells expressing BST2.
- diseases or conditions include lymphocytic tumors such as multiple myeloma and rheumatism.
- the pharmaceutical composition of the present invention can selectively act on autoantibody-producing cells, ie, plasma cells (plasma B cells) expressing BST2.
- the human monoclonal antibody of the present invention can be applied to prolong the life of patients suffering from primary local cancer.
- FIG. 1 shows the reactivity of the anti-human BST2 antibody to the RPMI8226 cell line.
- FIG. 2 shows the internalization-inducing activity of an anti-human BST2 antibody (7-90G).
- FIG. 3 is a micrograph showing anti-BST2 antibody internalized in RPMI8226 cells after 15 minutes of 37 culture.
- FIG. 4 shows the nucleotide sequence of full-length human BST2 DNA.
- FIG. 5 shows the amino acid sequence of full-length human BST2.
- FIG. 6 is a diagram showing 500 t1H NMR of the synthesized maytansine compound.
- FIG. 7 is a graph showing the antitumor effect of maytansine-conjugated b-76-8 antibody on a human myeloma mouse model.
- Full-length human BST2 DNA (SEQ ID NO: 1) was modified by polymerase chain reaction (PCR) to add a Not I sequence at its 5 'end and an Xba I and termination codon at its 3' end. .
- PCR polymerase chain reaction
- K0D-Plus- (Toyobo) DNA polymerase and human bone marrow-derived PolyA + RNA CDNA (approximately 20 ng) synthesized from Superscript II (manufactured by Clontecli) using Superscript II (manufactured by Gibco-BRL) as type III at 94 ° C, 15 seconds; 50 ° (30 seconds; and 68 ° (: 1 minute)
- the modified BST2 sequence was isolated as a NotI-XbaI fragment and lig
- Soluble BST2 protein was prepared by the following method in an expression system using baculovirus.
- FLAG N-terminal-DYKDDDDK-C-terminal, Brizzard et al., Biotechniues (1994) 16: 730
- FLAG-sBST2 FLAG at the N-terminus of the BST2 partial peptide having an amino acid sequence of 54-180 (amino acid number 54-180 of SEQ ID NO: 2)
- FLAG-sBST2 FLAG at the N-terminus and dal thione-S-transferase at the C-terminus
- GST Smith et al., Gene (1988) 67:31
- FLAG-SBST2-GST Two types of soluble BST2 expression plasmids were prepared.
- the FLAG-SBST2 vector has the following DNA sequence consisting of a secretory signal sequence at the 5 'end, a Bglll sequence at the 5' end to add a FLAG codon, and a BamHI E sequence at the 3 'end.
- the reaction was carried out for 1 minute at seconds; and 72. Modified BST2 sequence was isolated as a BamHI-Notl fragment. Then, the SI ato Flag fragment and the BamHI-Notl fragment were ligated to a pFastBacl (GIBC0) vector cleaved with Bglll and Notl enzymes. The resulting plasmid was named pFastBacl / FBST2.
- FLAG-SBST2-GST adds the BamHI sequence at the 5 'end and the NotI sequence at the 3' end, so that the primers 5'_CGAGGATCCCATATGCGGGACGGCCTTCGGGC-3 '(SEQ ID NO: 6) and 5'_AAGGAAAAGCGGCCGCCTGCAGCAGAGCGCTGAGG_3' No. 7) was used to modify by PCR.
- PCR was performed using EX-Taci polymerase (Takara Shuzo Co., Ltd.) and 20 ng of pFastBacl / FBS for 30 cycles at 94 ° C, 30 seconds; 56 ° C, 30 seconds; and 72 ° C, 1 minute. I let it.
- the modified BST2 sequence was isolated as a BamHI-Notl fragment.
- a Notl sequence was added to the 5 'end, and a ⁇ I sequence was added to the 3' end.
- PCR was performed using EX-TaQ polymerase (Takara Shuzo Co., Ltd.) and 20 ng of pGEX plasmid (Amersham Pharmacia Biotech) for 30 cycles at 94 ° C, 30 seconds; 56, 30 seconds; and 72 ° C. The reaction was performed for 1 minute.
- the modified GST sequence was isolated as a Notl-Kpnl fragment, and the above-described BamHI-Notl fragment and Notl-Kpnl fragment were ligated into a BamHI-Kpnl-cleaved pFastBacl / FBST2 vector.
- the resulting plasmid was named pFastBacl / FBST2 / GST.
- the recombinant virus was prepared by a manual method using the expression vector prepared in Example 2 and BAC-T0-BAC Baculovirus Expression System manufactured by GIBC0B.RL.
- the obtained recombinant baculovirus was prepared by adding 0.3 ml of the recombinant baculovirus-containing supernatant to 5 ml of 3xl0 6 Sf9 cells (manufactured by Invitrogen) and adding 4 ml of the supernatant to a flask (T-Flask 25 cm 2 , manufactured by CORNING). After culturing for 27 days at 27 days, the culture supernatant was collected and the recombinant baculovirus was amplified. The same operation was performed until the target amount of virus was obtained. (Example 4) Expression of soluble human BST2
- soluble BST2 To express large amounts of soluble BST2, add 80 ml of the virus prepared in Example 3 to 800 ml of HiFive TM cells (lxlOVml, manufactured by Invitrogen), culture at 27 ° C for 60 hours, and culture supernatant. Was recovered. The collected supernatant was centrifuged and then passed through a 0. PES filter (manufactured by CORNING) to remove extraneous waste such as cells.
- soluble BST2 (FLAG-SBST2, FLAG-SBST2-GST) from the culture supernatant prepared in Example 4 was performed by the following method.
- the culture supernatant containing soluble BST2 was purified using a FLAG M2 affinity column (manufactured by SIGMA) according to the instructions provided with PBS (-) as the adsorption buffer and 0.1 M glycine-HCl buffer as the elution buffer.
- the solution was purified using affinity (pH 3).
- the eluted fraction was adjusted to around pH 7.2 by adding 1 M Tris-HCl (pH 8.0).
- the prepared antibody solution was replaced with PBS (-) using a dialysis membrane (10000 cuts, manufactured by Spectrum Laboratories), and sterilized by filtration through a membrane filter with a pore size of 0, MILLEX-GV (manufactured by MILLIP0RE).
- a single band of purified FLAG-sBST2 and FLAG_sBST2-GST was obtained by SDS / PAGE electrophoresis.
- mice used for immunization had a homozygous genetic background for both endogenous Ig heavy chain rupture and / c light chain disruption, and a chromosome 14 fragment containing the human Ig heavy chain locus. (SC20)) and the human Ig / c chain transgene (KCo5).
- SC20 human Ig heavy chain locus
- KCo5 human Ig / c chain transgene
- This mouse was produced by crossing a mouse with a human Ig heavy chain locus (strain A) and a mouse with a human Ig / c chain transgene (strain mouse.
- SC20 a report by Tomizuka et al. (Tomizuka.
- strain B is homozygous for both endogenous Ig heavy chain and ⁇ light chain disruption, and human Ig K chain.
- Male mice of strain A and female mice of strain B Or strain A female mice and strain B males The following solids (Ishida & Lonberg, IBCs 11th Ant Body Engineering, Abstract 2000) obtained by crossing mice and in which human Ig heavy chain and ⁇ light chain are simultaneously detected in serum Used for immunization experiments.
- the human antibody-producing mouse can be obtained from Kirin Brewery Co., Ltd. under a contract.
- the preparation of the monoclonal antibody in this example was prepared according to a general method as described in, for example, Introduction to Monoclonal Antibody Experimental Procedures (written by Tamoe Ando et al., Published by Kodansha 1991).
- human BST2 as an immunogen, the pTracer-CMV / hBST2 vector prepared in Example 1 and FLAG-SBST2 prepared in Example 5 were used.
- a human antibody-producing mouse that produces human immunoglobulin prepared in Example 6 was used as the animal to be immunized.
- the pTracer-CMV / hBST2 vector (10 g / animal) prepared in Example 1 is introduced and expressed into human antibody-producing mice using Trans IT TM In Vivo Gene Delivery System Reagent (Takara Shuzo Co., Ltd.). First immunization. After the initial immunization, the vector was transduced and expressed three times a week, and boosted. Further, the FLAG-SBST2 (10 Mg) prepared in Example 5 was boosted by tail vein injection, and the FLAG-SBST2 (10/2 g) was similarly treated three days before the acquisition of spleen cells described below. I was immunized.
- the spleen was surgically obtained from the immunized mouse, and the collected spleen cells were mixed with mouse myeloma SP2 / 0 (ATCC No .: CRL1581) at a ratio of 5: 1, and polyethylene glycol 1500 (Boehringer Mannheim) was used as a fusion agent.
- a number of hybridomas were produced by cell fusion using The selection of the hybridoma was performed using a DMEM medium containing HAT containing 10% fetal calf serum (Fetal Calf Serum, FCS) and hypoxanthine (H), aminopterin (A), and thymidine (T) (Gibco BRL). ).
- a single clone was obtained by a limiting dilution method using HT-containing DMEM medium.
- the culture was performed in a 96-well microtiter plate (manufactured by Becton Dickinson).
- Selection (screening) of hybridoma clones producing anti-human human monoclonal antibodies and characterization of the human monoclonal antibodies produced by each hybridoma were carried out by enzyme-linked immunosorbent assay (ELISA) and fluorescence-activated This was done by measuring in the evening (FACS).
- ELISA enzyme-linked immunosorbent assay
- each hybridoma producing the human anti-human hBST2 monoclonal antibody of the present invention is represented by the symbol Was used.
- the following hybridoma clones represent a single clone: 2-1L, 2-20J, 5-71, 5-85H, 7-90G, 8-190, b-76-8 or 9-16-1.
- Hypri-Doma clones 5-71, 7-90G, 9-16-1 and b-76-8 were transferred to the National Institute of Advanced Industrial Science and Technology, Patent Organism Depositary (1-chome, Higashi, Tsukuba, Ibaraki, Japan) International deposit was made at No. 1, 1 Central 6) under the provisions of the Budapest Treaty.
- Ibri dorma clones 5-71 and 7-90G are accession numbers FERM BP-7417 and FEM BP-7418, respectively (as of December 26, 2000)
- hybrididoma clones 9-16-1 and b-76- 8 are the accession numbers FERM BP-7821 and FERM BP-7822, respectively (as of December 7, 2001).
- Example 8 Detection of monoclonal antibody having human immunoglobulin ⁇ chain FLAG-SBST2-GST (1 g / ml 50 mM Na 2 HCO 3> Pell) prepared in Example 5 was transferred to a 96-well microplate for ELISA (Maxi sorp , Nunc) and incubated at room temperature for 30 minutes to adsorb FLAG-SBST2-GST to the microplate. Next, the supernatant was discarded, a blocking reagent (SuperBlock TM Blocking Buffer, manufactured by PIERCE) was added to each well, and the mixture was incubated at room temperature for 10 minutes to block a site where FLAG-sBST2-GST was not bound. Thus, a microplate in which each well was coated with FLAG-SBST2-GST was prepared.
- ELISA Maxi sorp , Nunc
- TMB coloring substrate solution
- the FLAG-SBST2-GST (1 i / ml 50 mM Na 2 HCO 3 , 50 1 / well) prepared in Example 5 was added to each well of a 96-well microplate for ELISA (Maxi soriK Nunc), and the mixture was added at room temperature for 30 minutes. After incubating, FLAG-SBST2-GST was adsorbed to the microplate. Next, the supernatant was discarded, and a blocking reagent (SuperBlock TM Blocking Buffer, manufactured by PIERCE) was added to each well, followed by incubation at room temperature for 10 minutes. Each well was washed twice with PBS-T.
- SuperBlock TM Blocking Buffer manufactured by PIERCE
- the culture supernatant (501) of each hybridoma was added to each well of the microplate coated with FLAG-SBST2-GST, reacted for 30 minutes, and then each well was washed twice with PBS-T. Next, each well was subjected to a peroxidase-labeled anti-human IgG1 antibody, anti-human IgG2 antibody, anti-human IgG3 antibody or anti-human IgG4 antibody (diluted 2,000-fold, 50 / well, respectively). , The Binding Site) and incubated at room temperature for 30 minutes. After washing three times with PBS-T, a substrate buffer (TMB, well, DAK0) was added to each well, and incubated at room temperature for 20 minutes.
- TMB substrate buffer
- Myeloma-derived cell line RPMI8226 (ATCC CCL-
- Negative controls were prepared using human IgGl antibody (manufactured by Sigma) or human IgG4 antibody (manufactured by Sigma) at a concentration of 2/1111 in a hybridoma culture medium, and then added to 50 / zl according to each subclass. Incubated for 30 min. After washing twice with SB, 0.0125 mg / ml of RPE fluorescently labeled ⁇ heron anti-human IgL / F (ab ') 2 antibody (manufactured by DAK0) 301 was added, and incubated at ice temperature for 30 minutes.
- the culture supernatant containing the anti-BST2 antibody was prepared by the following method.
- Anti-BST2 antibody-producing hybridomas were analyzed by using insulin (5 g / ml, Gibco BRL), human transferrin (5 g / ml, Gibco BRL), ethanolamine (0.01 mM, Sigma), sodium selenate (2.5x10- 5 ⁇ , sigma) were habituated to contain eRDF medium (Kyokuto pharmaceutical Co., Ltd.).
- the cells were cultured in a spinner flask. When the viable cell ratio of the hybridoma reached 90%, the culture supernatant was recovered.
- the collected supernatant was subjected to a lO / zm and 0.2 l filter (manufactured by Gelman Science) to remove miscellaneous waste such as hybridoma.
- the anti-BST2 antibody was purified from the culture supernatant by the following method. Using a Hyper D Protein II column (manufactured by NGK), the culture supernatant containing the anti-BST2 antibody was used as the adsorption buffer in PBS (-), and the elution buffer was 0.1 M sodium citrate buffer (pH It was affinity purified using 3). The eluted fraction is 1 MTris_HCl (H 8.0) was added to adjust the pH to around 7.2. The prepared antibody solution was replaced with PBS (-) using a dialysis membrane cut, Spectrum Laboratories), and sterilized by filtration through a 0.22 xm membrane filter, MILLEX-GV (MILLIPORE). Purified anti-BST2 antibody was obtained. The concentration of the purified antibody was calculated by measuring the absorbance at 280 MI and setting 1 mg / ml to 1.450D.
- Fluorescent labeling of the anti-BST2 antibody was performed by the following method. Alexa Fluor TM 488 (Molecular Probes) was bound to the anti-BST2 antibody prepared in Example 12 according to the attached instructions. To 0.5 ml of 2 mg / ml anti-BST2 antibody was added 501 1M carbonate buffer, mixed with Alexa Fluor TM 488, and reacted with stirring for 1 hour at room temperature. Hydroxylamine was added to stop the reaction, and the mixture was applied to a gel filtration column (NAP5, manufactured by Amersham Pharmacia Biotech) to remove Alexa Fluor TM 488 unbound to the antibody. Under these conditions, six fluorescent substances bound to one antibody molecule. The fluorescently labeled antibody bound to RPMI8226, and its binding activity was equivalent to the unlabeled antibody.
- Alexa Fluor TM 488 Molecular Probes
- Antigen internalization-inducing activity of an antibody was determined by Andrzej et al. (LI ⁇ uno l.
- Unbound Mexa Fluor TM 488-labeled anti-BST2 antibody was removed from cells by washing four times with ice-cold RPMI medium containing 10% FCS. After resuspending in RPMI medium containing 10% FCS warmed to 37 ° C, culture at 37 ° C. After 0, 15, 30, 60, and 120 minutes of incubation, use ice-cold SB to stop internalization. Washed twice. To detect the antibody bound to hBST2 on the cell surface, add 0.0125 mg / ml RPE fluorescently labeled ⁇ egan anti-human IgL ⁇ F (ab ') 2 antibody (DAK0) 30/21 Incubation for 30 minutes on ice.
- the cells were suspended in a FACS buffer solution, and the average fluorescence intensity of each cell was measured by FACScan (manufactured by Becton Dickinson).
- the background level was set using the Alexa Flour TM 488-labeled IgGl ⁇ antibody and RPMI8226 strain as controls for the average fluorescence intensity at the start of cultivation at 37 ° C for samples treated as described above, for Alexa 3-5, for RPE Then, the sensitivity was set as shown in Figs. Figure 2 shows the results.
- the average fluorescence intensity of Alexa Fluor TM 488 did not decrease when cultured at 3rc, the average fluorescence intensity of the RPE fluorophore, which indicates the amount of BST2 / anti-BST2 antibody immune complex on the cell surface, was 37%.
- the average fluorescence intensity of the RPE fluorescent substance decreased to less than 50% at 15 minutes of culture, and the anti-BST2 antibody (7-90G) efficiently internalized BST2. Antibodies.
- the state of the internalization was observed by fluorescence microscopy (Fig. 3).
- N- methyl -N- of 26mg prepared in a separate method according References (methyl-di Chio prop Noiru) - L-Aranin was dissolved in CH 2 C 1 2 of 3 ml, here dicyclohexyl of 30mg Kishiruka Rupojiimido ( 2 equivalents) and 1 M zinc chloride 201 (1 equivalent) were added and stirred at room temperature for 30 minutes. However, the reaction did not proceed under these conditions, so the amount of 1 M zinc chloride added was changed to mn ⁇ (5 equivalents), and the mixture was stirred at room temperature for 30 minutes.
- 11.8 mg of maytansinol was dissolved in 1 ml of CH 2 C 12 and added to carry out an esterification reaction.
- FIG. 6 shows 500 band z 1H NMR of the obtained May-SS-Me form.
- IC5 of May -SS-Me obtained in the cytotoxic activity test of human myeloma cell line IM9 described in Example 19. Is ⁇ , which is less than 1/100 that of ansami tocin. P-3.
- the introduced PDP group was 3.4 molecules / antibody.
- the May-SH (170 g / 800 L) prepared in Example 16 and the PDP-i-dani b-76-8 (10 mg / 9 mL) prepared in Example 17 were reacted at 4 ° C. for 40 hours.
- the reaction solution was applied to a Sepliadex TM G-25 column equilibrated with a phosphate buffer (pH 7.4) to remove unreacted May-SH.
- Dithiothreitol was added to a part of the obtained sample so as to be ImM, and reacted at room temperature for 5 minutes. After the reaction, the absorbance of the released pyridine-2-thione at 343 nm was measured, and the molar concentration of the PDP group present in the reaction system was quantified.
- the introduced maytansine compound was 1.8 molecules / antibody.
- Cysteine was added to a concentration of 0.1 M, and the reaction solution was equilibrated with phosphate buffer (PH7.4). Maytansine binding over time! )
- the -76-8 antibody ( May-b-76-8) was purified.
- IM9 cells human myeloma cell line IM9 cells (ATCC CCL-159) was examined in the same manner as in Example 11. As a result, the May-b-76-8 antibody showed the same reactivity as the b-76-8 antibody.
- the anti-tumor activity of the May-b-76-8 antibody was performed as follows. In each 96-well flat-bottomed plate (manufactured by Becton Dickinson), 2 x10 5 cells / ml of IM9 cells were added to 100 // 1 and b-76-8 antibody, May-b-76-8 antibody, or control human. IgGl was added, and the cells were cultured in a carbon dioxide incubator for 24 hours.
- MTS (3- (4,5-dimethylthiylthiazol-2-yl) -5- (3carboxymethoxyphenyl) -2- (4-sulphophenyl) -2H-tetrazolium, manufactured by FLOMEGA)
- the solution was added to each well and incubated for an additional 2 hours.
- the surviving cells were then measured for absorbance at a wavelength of 490 nm using a microplate reader (MTP-300, manufactured by Corona Electric).
- MTP-300 microplate reader
- the antibody to be administered was prepared at 800 g / ml using filtered and sterilized PBS (-), and used as the antibody to be administered.
- mice Human myeloma-transplanted mice were prepared using SCID mice (CLEA Japan) to prepare human myeloma cell line IM9 cells at 2.5 ⁇ 10 7 cells / ml with PBS ( ⁇ ).
- the IM9 cell solution 200 / zl was injected from the tail vein to a SCID mouse (female, 6 weeks old) (CLEA Japan) to which anti-ashia mouth GM1 (manufactured by Wako Pure Chemical) 100 1 was administered into the tail vein the day before.
- Antibodies prepared between day 6 and day 10 after IM9 cell transplantation were administered to these mice intravenously 200 11 1 each day.
- the anti-tumor effect of the May-b-76_8 antibody was evaluated by the survival time of mice.
- the PBS (-) control group and the isotype control In the human IgGl-administered group, death was observed around 20 days after IM9 cell transplantation. In the PBS (-)-administered group, death died on the 22nd day after transplantation, and the same was observed in the group administered with isotype control IgGl. Survival was observed.
- the b-76-8 antibody-administered group showed a longer survival time compared to the control group (p ⁇ 0.01, Logrank test).
- the monoclonal antibody of the present invention has a characteristic of binding to the human BST2 antigen on the cell surface and being localized inside the cell by internalization, a therapeutically useful drug bound to this antibody is used as a BST2 Can be efficiently delivered into cells such as multiple myeloma cells, lymphoid tumor cells, and primary local cancer cells that express the protein on the cell surface, and have a new effect on the treatment of difficult-to-treat diseases. It has the advantage of providing a therapeutic agent based on a mechanism.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002558389A JP4450555B2 (ja) | 2000-12-28 | 2001-12-26 | 新規モノクローナル抗体 |
US10/451,947 US7592005B2 (en) | 2000-12-28 | 2001-12-26 | Monoclonal antibody |
EP01273341A EP1354896B1 (en) | 2000-12-28 | 2001-12-26 | Monoclonal antibody directed against the human bst2 antigen |
AT01273341T ATE457318T1 (de) | 2000-12-28 | 2001-12-26 | Gegen das menschliche bst2 antigen gerichteter monoklonaler antikörper |
DE60141297T DE60141297D1 (de) | 2000-12-28 | 2001-12-26 | Gegen das menschliche bst2 antigen gerichteter monoklonaler antikörper |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000403245 | 2000-12-28 | ||
JP2000-403245 | 2000-12-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002057316A1 true WO2002057316A1 (fr) | 2002-07-25 |
Family
ID=18867405
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2001/011493 WO2002057316A1 (fr) | 2000-12-28 | 2001-12-26 | Nouvel anticorps monoclonal |
Country Status (6)
Country | Link |
---|---|
US (1) | US7592005B2 (ja) |
EP (1) | EP1354896B1 (ja) |
JP (1) | JP4450555B2 (ja) |
AT (1) | ATE457318T1 (ja) |
DE (1) | DE60141297D1 (ja) |
WO (1) | WO2002057316A1 (ja) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2006008886A1 (ja) * | 2004-06-11 | 2008-05-01 | Sbiバイオテック株式会社 | インターフェロン産生細胞の活性調節剤 |
WO2009051201A1 (ja) * | 2007-10-16 | 2009-04-23 | Sbi Biotech Co., Ltd. | 抗bst2抗体 |
EP1689846A4 (en) * | 2003-10-10 | 2010-08-04 | Immunogen Inc | METHOD FOR THE APPLICATION OF SPECIFIC CELL POPULATIONS USING UNCLEANED LINKER CONJUGATES OF THE CELL BINDING AGENT MAYTANSINOID, THE CONJUGATES, AND METHOD FOR THE PRODUCTION OF THE CONJUGATES |
WO2011108502A1 (ja) | 2010-03-02 | 2011-09-09 | 協和発酵キリン株式会社 | 改変抗体組成物 |
US8337856B2 (en) | 2000-03-16 | 2012-12-25 | Immunogen, Inc. | Methods of treatment using anti-ERBB antibody-maytansinoid conjugates |
JP2014502955A (ja) * | 2010-10-20 | 2014-02-06 | オックスフォード ビオトヘラペウトイクス エルティーディー. | 抗体 |
WO2018158716A1 (en) | 2017-03-02 | 2018-09-07 | Cadila Healthcare Limited | Novel protein drug conjugate formulation |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO347360B1 (no) * | 2003-10-10 | 2023-09-25 | Immunogen Inc | Cellebindingsmiddelmaytansinoid-konjugat med formel trastuzumab-SMCC-DM1 eller trastuzumab-SIABDM1, fremgangsmåte for fremstilling av disse og en in vitro fremgangsmåte for å styre maytansinoider til en valgt cellepopulasjon eller for å eliminere celler, samt anvendelse. |
US20100143899A1 (en) * | 2005-05-17 | 2010-06-10 | University Of Vermont And State Agricultural College | Methods and products for diagnosing cancer |
CA2660795C (en) * | 2006-09-18 | 2014-11-18 | Xencor, Inc. | Optimized antibodies that target hm1.24 |
US8445442B2 (en) * | 2007-04-26 | 2013-05-21 | University Of Vermont And State Agricultural College | CCL18 and CCL3 methods and compositions for detecting and treating cancer |
EP3692988A3 (en) | 2008-03-18 | 2020-10-14 | Genentech, Inc. | Combinations of an anti-her2 antibody-drug conjugate and 5-fu, anti-vegf antibody, carboplatin or abt-869 and methods of use |
BRPI0913045A2 (pt) * | 2008-05-23 | 2017-05-23 | Fit Biotech Oy | vetor de expressão codificador de alfa-vírus replicase e uso do mesmo como adjuvante imunológico |
CN107619443B (zh) * | 2016-07-14 | 2020-08-14 | 深圳宾德生物技术有限公司 | 抗人和鼠cd317的单克隆抗体及其制备方法和应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998037913A1 (fr) * | 1997-02-28 | 1998-09-03 | Chugai Seiyaku Kabushiki Kaisha | Inhibiteurs d'activation de lymphocytes |
JPH1192399A (ja) * | 1997-09-24 | 1999-04-06 | Chugai Pharmaceut Co Ltd | 骨髄腫治療剤 |
WO1999043703A1 (fr) * | 1998-02-25 | 1999-09-02 | Chugai Seiyaku Kabushiki Kaisha | Technique de dosage immunochimique de l'anticorps anti-hm1.24 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA76934C2 (en) * | 1996-10-04 | 2006-10-16 | Chugai Pharmaceutical Co Ltd | Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody |
HUP0001136A3 (en) | 1997-02-12 | 2002-02-28 | Chugai Pharmaceutical Co Ltd | Remedies for lymphocytic tumors |
US6306393B1 (en) * | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
-
2001
- 2001-12-26 WO PCT/JP2001/011493 patent/WO2002057316A1/ja active Application Filing
- 2001-12-26 EP EP01273341A patent/EP1354896B1/en not_active Expired - Lifetime
- 2001-12-26 JP JP2002558389A patent/JP4450555B2/ja not_active Expired - Fee Related
- 2001-12-26 DE DE60141297T patent/DE60141297D1/de not_active Expired - Lifetime
- 2001-12-26 AT AT01273341T patent/ATE457318T1/de not_active IP Right Cessation
- 2001-12-26 US US10/451,947 patent/US7592005B2/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998037913A1 (fr) * | 1997-02-28 | 1998-09-03 | Chugai Seiyaku Kabushiki Kaisha | Inhibiteurs d'activation de lymphocytes |
JPH1192399A (ja) * | 1997-09-24 | 1999-04-06 | Chugai Pharmaceut Co Ltd | 骨髄腫治療剤 |
WO1999043703A1 (fr) * | 1998-02-25 | 1999-09-02 | Chugai Seiyaku Kabushiki Kaisha | Technique de dosage immunochimique de l'anticorps anti-hm1.24 |
Non-Patent Citations (1)
Title |
---|
KEIJI OKAZI ET AL.: "Localization and imaging of human plasmacytoma xenograts in severe combined immunodeficiency mice by a new murine monoclonal antibody, anti-hm1.24", TOKUSHIMA JOURNAL OF EXPERIMENTAL MEDICINE, vol. 43, no. 1-2, 1996, pages 7 - 15, XP002912306 * |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8337856B2 (en) | 2000-03-16 | 2012-12-25 | Immunogen, Inc. | Methods of treatment using anti-ERBB antibody-maytansinoid conjugates |
US8563509B2 (en) | 2003-10-10 | 2013-10-22 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugates |
US7989598B2 (en) | 2003-10-10 | 2011-08-02 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugates |
US8685920B2 (en) | 2003-10-10 | 2014-04-01 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugates |
EP2596803A3 (en) * | 2003-10-10 | 2013-09-11 | ImmunoGen, Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
US8163888B2 (en) | 2003-10-10 | 2012-04-24 | Immunogen, Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugates |
US8198417B2 (en) | 2003-10-10 | 2012-06-12 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugates |
EP1689846A4 (en) * | 2003-10-10 | 2010-08-04 | Immunogen Inc | METHOD FOR THE APPLICATION OF SPECIFIC CELL POPULATIONS USING UNCLEANED LINKER CONJUGATES OF THE CELL BINDING AGENT MAYTANSINOID, THE CONJUGATES, AND METHOD FOR THE PRODUCTION OF THE CONJUGATES |
US10844135B2 (en) | 2003-10-10 | 2020-11-24 | Immunogen, Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said |
JPWO2006008886A1 (ja) * | 2004-06-11 | 2008-05-01 | Sbiバイオテック株式会社 | インターフェロン産生細胞の活性調節剤 |
US8435530B2 (en) | 2004-06-11 | 2013-05-07 | Sbi Biotech Co., Ltd. | Methods for suppressing activity of activated interferon-producing cells |
WO2009051201A1 (ja) * | 2007-10-16 | 2009-04-23 | Sbi Biotech Co., Ltd. | 抗bst2抗体 |
US8529896B2 (en) | 2007-10-16 | 2013-09-10 | Sbi Biotech Co., Ltd. | Anti-BST2 antibody |
CN101952426B (zh) * | 2007-10-16 | 2014-04-16 | Sbi生物技术有限公司 | 抗bst2抗体 |
JP5558825B2 (ja) * | 2007-10-16 | 2014-07-23 | Sbiバイオテック株式会社 | 抗bst2抗体 |
WO2011108502A1 (ja) | 2010-03-02 | 2011-09-09 | 協和発酵キリン株式会社 | 改変抗体組成物 |
JP2014502955A (ja) * | 2010-10-20 | 2014-02-06 | オックスフォード ビオトヘラペウトイクス エルティーディー. | 抗体 |
WO2018158716A1 (en) | 2017-03-02 | 2018-09-07 | Cadila Healthcare Limited | Novel protein drug conjugate formulation |
Also Published As
Publication number | Publication date |
---|---|
US7592005B2 (en) | 2009-09-22 |
ATE457318T1 (de) | 2010-02-15 |
EP1354896A4 (en) | 2004-06-16 |
EP1354896A1 (en) | 2003-10-22 |
US20040136982A1 (en) | 2004-07-15 |
DE60141297D1 (de) | 2010-03-25 |
JPWO2002057316A1 (ja) | 2004-05-20 |
EP1354896B1 (en) | 2010-02-10 |
JP4450555B2 (ja) | 2010-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101529810B1 (ko) | 항체-약물 접합체 | |
AU2014361856A1 (en) | Novel anti-DPEP3 antibodies and methods of use | |
AU2015249887A1 (en) | Novel anti-RNF43 antibodies and methods of use | |
JP6898925B2 (ja) | Asct2特異的結合分子及びその使用 | |
WO2007114496A1 (ja) | 新規抗cd98抗体 | |
US20200255536A1 (en) | Target for b-cell disorders | |
WO2002057316A1 (fr) | Nouvel anticorps monoclonal | |
JP2021533732A (ja) | Sema4d抗体及びその製造方法と使用 | |
JP2023541473A (ja) | 抗4-1bb-抗pd-l1二重特異性抗体、ならびにその医薬組成物および使用 | |
TWI846095B (zh) | 抗cd47-cldn18.2雙特異性抗體及其用途 | |
JP2024100838A (ja) | 抗ラムダ骨髄腫抗原(lma)発現がん及び自己免疫障害を処置するlma結合タンパク質 | |
CN113045659B (zh) | 抗cd73人源化抗体 | |
CN106687476B (zh) | 抗brdu抗体及使用方法 | |
JP2023544140A (ja) | 新規の抗クローディン18抗体 | |
CN115304680A (zh) | 基于Pep42构建的双特异性细胞接合器分子的制备及其应用 | |
US20240091262A1 (en) | Mage-a4 peptide dual t cell engagers | |
CN111840571B (zh) | 一种抗体药物偶联物及其用途 | |
WO2023236968A1 (zh) | Cd39/cd73双特异性抗原结合蛋白及其用途 | |
EP4397685A1 (en) | Anti-cd3 humanized antibody | |
WO2024093147A1 (zh) | 一种特异性结合CD44的v5外显子的抗体及其用途 | |
JP2024534681A (ja) | 抗cd39抗体ー薬物複合体及びその使用 | |
CA3200813A1 (en) | Development of new tumor engager therapeutic drug and use thereof | |
TW202200209A (zh) | 用於優化之藥物接合之經修飾的結合多肽 | |
CN113321730A (zh) | Cldn18.2抗体及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002558389 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10451947 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001273341 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001273341 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |